

Medicare Advantage Medical Benefit Drug Policy



An independent licensee of the Blue Cross and Blue Shield Association

Medical benefit drug policies are a source for Blue Cross and Blue Shield of Nebraska Medicare Advantage medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and therefore subject to change.

Effective Date: 02/02/2023

Keytruda[®] (pembrolizumab)

HCPCS: J9271

Policy:

Requests must be supported by submission of chart notes and patient specific documentation.

- A. Coverage of the requested drug is provided when all the following are met:
 - a. Treatment must follow the FDA approved indications or National Comprehensive Cancer Network (NCCN) guidelines when it is a Category 1 or 2A recommendation
 - i. Must be used with concomitant treatment according to FDA indication or NCCN Category 1 or 2A recommendation
 - b. Prescribed by or in consultation with an oncologist or hematologist
 - c. No prior failure of a programmed death receptor-1 (PD-1) inhibitor
 - d. Patient is not receiving therapy for a chronic condition, such as an autoimmune disease, that requires treatment with a systemic immunosuppressant

- B. Quantity Limitations, Authorization Period and Renewal Criteria
 - a. Quantity Limits: Align with FDA recommended dosing
 - b. Authorization Period: Aligns with FDA recommended or guideline supported treatment duration and provided for at least 60 days and up to 6 months at a time
 - c. Renewal Criteria:
 - i. Treatment continued until unacceptable toxicity or disease progression occurs
 - ii. Renewal beyond 24 months of total therapy will be considered according to FDA approved drug labelling

***Note: Coverage may differ for Medicare Part B members based on any applicable criteria outlined in Local Coverage Determinations (LCD) or National Coverage Determinations (NCD) as determined by Center for Medicare and Medicaid Services (CMS). See the CMS website at <http://www.cms.hhs.gov/>. Determination of coverage of Part B drugs is based on medically accepted indications which have supported citations included or approved for inclusion determined by CMS approved compendia.

Background Information:

- Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the following:
 - For the treatment of patients with unresectable or metastatic melanoma
 - For the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB, IIC, or III melanoma following complete resection
 - In combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations
 - In combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC
 - As a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) \geq 1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is:
 - Stage III where patients are not candidates for surgical resection or definitive chemoradiation or
 - Metastatic
 - As a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS \geq 1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Keytruda
 - In combination with platinum and fluorouracil for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell cancer (HNSCC)
 - As a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) \geq 1] as determined by an FDA-approved test
 - As a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy
 - For the treatment of adult patients with relapsed or refractory classic Hodgkin lymphoma (cHL)
 - For the treatment of pediatric patients with refractory cHL or cHL that has relapsed after 2 or more lines of therapy
 - For the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL) or who have relapsed after 2 or more prior lines of therapy
 - For the treatment of patients with locally advanced or metastatic urothelial carcinoma who
 - Are not eligible for any platinum-containing chemotherapy OR

- Have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
- For the treatment of patients with Bacillus Calmette-Guerin (BCG) unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy
- For the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options
- For the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test
- For the treatment of locally advanced, unresectable, or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, as first-line treatment
- For the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either:
 - In combination with platinum- and fluoropyrimidine-based chemotherapy OR
 - As a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥ 10) as determined by an FDA-approved test
- In combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA-approved test
- As a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 [Combined Positive Score (CPS) ≥ 1] as determined by an FDA-approved test
- For the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib
- For the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC)
- In combination with axitinib, for the first-line treatment of patients with advanced renal cell carcinoma (RCC)
- In combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC
- For the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions
- In combination with lenvatinib, for the treatment of patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) as determined by an FDA-approved test or not MSI-H, who have disease

progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation

- As a single agent, for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation
 - For the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥ 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options
 - For the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced sCSS that is not curable by surgery or radiation
 - For the treatment of patients with high-risk early-stage triple negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery
 - In combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥ 10] as determined by an FDA approved test
- The National Comprehensive Cancer Network (NCCN) guidelines category 1 and 2A recommendations are based on uniform NCCN consensus that the recommendations are appropriate. Treatment regimens have been studied and shown to be efficacious when administered as listed in the guidelines. Category 2B and 3 recommendations do not have a high level of evidence to support use and also do not have a uniform consensus from the NCCN panel that the recommendations are appropriate.
 - There are no studies to support use of Keytruda following failure. NCCN treatment guidelines also do not recommend use of Keytruda or other PD-L1 checkpoint inhibitors following a previous failure.
 - Keytruda has not been studied in patients on chronic immunosuppressant therapy and therefore, should not be used in patients on chronic immunosuppressants.

References:

1. Keytruda [prescribing information]. Whitehouse Station, NJ: Merck and Company, Inc.; December 2022.
2. National Comprehensive Cancer Network. Uterine neoplasms (Version 1.2023). 2022 Dec 22. Available at: https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf. Accessed on December 28, 2022.
3. National Comprehensive Cancer Network. Breast cancer (Version 4.2022). 2022 June 21. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed on December 28, 2022.
4. National Comprehensive Cancer Network. Cutaneous melanoma (Version 1.2023). 2022 Dec 22. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf. Accessed on December 28, 2022.
5. National Comprehensive Cancer Network. Non-small cell lung cancer (Version 1.2023). 2022 Dec 22. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed on December 28, 2022.
6. National Comprehensive Cancer Network. Head and neck cancers (Version 1.2023). 2022 Dec 20. Available at: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed on December 28, 2022.
7. National Comprehensive Cancer Network. Hodgkin lymphoma (Version 2.2023). 2022 Nov 8. Available at: https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf. Accessed on December 28, 2022.
8. National Comprehensive Cancer Network. B-cell lymphomas (Version 5.2022). 2022 July 12. Available at: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed on December 28, 2022.

9. National Comprehensive Cancer Network. Bladder cancer (Version 3.2022). 2022 December 21. Available at: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed December 28, 2022.
10. National Comprehensive Cancer Network. Colon cancer (Version 2.2022). 2022 Oct 22. Available at: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed on December 28, 2022.
11. National Comprehensive Cancer Network. Gastric cancer (Version 2.2022). 2022 Jan 11. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed on December 28, 2022.
12. National Comprehensive Cancer Network. Esophageal and esophagogastric junction cancer (Version 5.2022). 2022 Dec 5. Available at: https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. Accessed on December 28, 2022.
13. National Comprehensive Cancer Network. Cervical cancer (Version 1.2023). 2022 Dec 23. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf. Accessed on December 28, 2022.
14. National Comprehensive Cancer Network. Hepatobiliary cancers (Version 4.2022). 2022 Dec 9. Available at: https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed on December 28, 2022.
15. National Comprehensive Cancer Network. Merkle cell carcinoma (Version 2.2022). 2022 March 24. Available at: https://www.nccn.org/professionals/physician_gls/pdf/mcc.pdf. Accessed on December 28, 2022.
16. National Comprehensive Cancer Network. Squamous cell skin cancer (Version 2.2022). 2022 May 2. Available at: https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf. Accessed on December 28, 2022.
17. National Comprehensive Cancer Network. Kidney cancer (Version 3.2023). 2022 Sept 22. Available at: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed on December 28, 2022.
18. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. *Lancet*. 2014 Sep 20 ;384 (9948): 1109 - 17.
19. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. *NEJM*. 2015; 372: 2018 – 28.
20. Robert C. Pembrolizumab versus ipilimumab in advanced melanoma. *NEJM*. 2015; 372: 2521 - 32.
21. Kurzwaski G, Suchy J, Debnik T, et al. Importance of microsatellite instability (MSI) in colorectal cancer: MSI as a diagnostic tool. *Ann Oncol*. 2004; 15 (Suppl 4): iv283 - 4.
22. Savage KJ. Primary mediastinal large b-cell lymphoma. *The Oncologist*. 2006; 11: 488 - 95.

Policy History		
#	Date	Change Description
1.3	Effective Day: 02/02/2023	Updated approval length to allow for FDA recommended dosing for at least 60 days and up to 6 months at a time
1.2	Effective Date: 02/10/2022	Annual review of criteria was performed, no changes were made
1.1	Effective Day: 02/04/2021	Updated authorization periods to mirror the recommended treatment duration in the package insert
1.0	Effective Date: 2/06/2020	Annual Review

* The prescribing information for a drug is subject to change. To ensure you are reading the most current information it is advised that you reference the most updated prescribing information by visiting the drug or manufacturer website or <http://dailymed.nlm.nih.gov/dailymed/index.cfm>